Chugai Pharmaceutical Co., Ltd.
4519.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.65 | -376.59 | 4.64 | -1.92 |
| FCF Yield | 0.59% | 0.75% | 0.40% | 1.32% |
| EV / EBITDA | 57.79 | 87.24 | 79.12 | 86.49 |
| Quality | ||||
| ROIC | 6.66% | 4.98% | 5.15% | 4.67% |
| Gross Margin | 69.91% | 69.63% | 69.55% | 68.78% |
| Cash Conversion Ratio | 0.65 | 1.24 | 0.69 | 1.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.66% | -1.28% | 0.29% | 0.07% |
| Free Cash Flow Growth | -33.35% | 105.96% | -70.25% | 42.33% |
| Safety | ||||
| Net Debt / EBITDA | -2.53 | -3.55 | -3.01 | -4.16 |
| Interest Coverage | 3,088.74 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.37 | 0.38 | 0.39 |
| Cash Conversion Cycle | 245.91 | 258.92 | 258.57 | 313.30 |